Menu
ncarol.com
  • Home
  • Business
  • Health
  • Music
  • Real Estate
  • Finance
  • Financial
  • Loans
  • Stock Market
ncarol.com

'Spot Detective' – Check your spots this summer
ncarol.com/10200678

Trending...
  • Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
  • Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)
The Spot Detective - who are they The Spot Detective - freckle
The latest campaign urging Australians to get their skin checked

MELBOURNE, Australia & SYDNEY - ncarol.com -- OncoBeta, a leading medical device company specialising in innovative epidermal radioisotope therapies for non-melanoma skin cancer, has launched The Spot Detective campaign to rally Australians in the fight against skin cancer this summer.

With two out of three Australians diagnosed with skin cancer before the age of 701, it is vital for all Australians to have regular skin checks. The Spot Detective campaign is encouraging Australians to visit a Spot Detective – their GP, dermatologist or skin health specialist – to have their spots assessed and to learn about the various treatments available for those diagnosed with non-melanoma skin cancer.

Skin cancer occurs when skin cells are damaged, often from overexposure to ultraviolet (UV) radiation from the sun. There are three main types of skin cancer: basal cell carcinoma (BCC); squamous cell carcinoma (SCC) and melanoma.2 Australia has one of the highest melanoma rates in the world1, with one Australian dying from melanoma every six hours.3 A skin check can save your life.

OncoBeta's Australian Medical Director, Dr Sam Vohra, says, "Thankfully most skin cancers are treatable and most of us will know someone who has had a skin cancer. Today, there are a range of treatments available to patients in addition to surgery, some of which are painless*, only needing a single session† and non-invasive."4-6

The Spot Detective campaign is asking Australians to take action: if they see a skin spot that is suspicious, new, oddly shaped or has changed in colour then it's time to get it checked. The campaign includes a series of LIVE reads across 2GB and WSFM in Sydney and 3AW and Gold 104.3 in Melbourne, as well as a social media and digital marketing campaign, and free skin check pop-ups at various locations.

More on ncarol.com
  • Preston Dermatology & Skin Surgery Center Wins Gold and Bronze in Prestigious Annual DIAMOND Awards
  • David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
  • "Phinge Unveil™" Coming to Las Vegas to Showcase Netverse Patented Verified App-less Platform, AI & Modular Hardware Including Developer Conferences
  • Elizabeth McLaughlin, Founder and CEO of Red Wagon Group, named 2026 Presidential Leadership Scholar
  • U.S. Congressional Candidate Peter Coe Verbica on America's Asymmetric Crisis

"With one of the highest incidences of skin cancer in the world, Australians need to be vigilant with their skin. The Spot Detective campaign is a timely reminder to make sure you are protecting yourself from the sun, and if you notice any changes to your skin, check in with a skin health specialist," added Dr Vohra.

Another health initiative from OncoBeta, this public awareness campaign also encourages anyone diagnosed with non-melanoma skin cancer to be well informed about all treatments and discuss their most suitable options with a healthcare professional. OncoBeta's skin cancer therapy which utilises the rhenium-188 isotope is now available at private clinics at Melbourne and Sydney. Patients with difficult anatomic localisations of a tumour, such as the ear, nose or anywhere on the face, and those with larger lesions problematic for plastic surgery, may benefit from this non-invasive solution.

To find out more information on skin cancer, and to learn what treatments are available, visit: www.spotdetective.com.au

About OncoBeta® GmbH
OncoBeta® GmbH, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.

Find out more about the Rhenium-SCT® at www.oncobeta.com

Follow us on social media:

More on ncarol.com
  • Jones Sign Rebrands as Jones to Reflect Growth, Innovation, and Expanded Capabilities
  • Helping high-functioning women reduce mental load by redesigning broken life systems
  • $1 Million Share Repurchase Signals Confidence as Off The Hook YS Scales a Tech-Driven Platform in the $57 Billion U.S. Marine Market
  • Trends Journal's Top Trends of 2026
  • Tatt:Magic Unveils Breakthrough Tattoo Recovery System with Faster Healing, No Itch, and Vibrant Results

LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

*No reported pain.3
†
Complete tumour regression in 98.5% of lesions treated.

References:
1. Cancer Council. Understanding Skin Cancer. January 2020. https://www.cancercouncil.com.au/ (accessed October 2022).
2. Skin Cancer. Available at https://www.mayoclinic.org/diseases-conditions/skin-cancer/symptoms-causes/syc-20377605 [Accessed October 2022]
3. Melanoma Institute Australia. Melamoma Facts. https://melanoma.org.au/about-melanoma/melanoma-facts/ (accessed October 2022).
4. Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48(5):1511–1521.
5. Cipriani C, et al. J Dermatol Treat. 2020; DOI: 10.1080/09546634.2020.1793890.
6. Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.

Contact
Jane Morey
***@moreymedia.com.au


Source: OncoBeta GmbH
Filed Under: Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
  • Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
  • Japan's Patented "Hammock'n" Smartphone Band Targets Hand Fatigue From Long Phone Use
  • Reditus Group Introduces A New Empirical Model for Early-Stage B2B Growth
  • CCHR: Harvard Review Exposes Institutional Corruption in Global Mental Health
  • Goatimus Launches Dynamic Context: AI Prompt Engineering Gets Smarter
  • Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)
  • RNHA Affirms Support for President Trump as Nation Marks Historic Victory for Freedom
  • American Laser Study Club Announces 2026 Kumar Patel Prize in Laser Surgery Recipients: Ann Bynum, DDS, and Boaz Man, DVM
  • Lineus Medical Completes UK Registration for SafeBreak® Vascular
  • Canyons & Chefs Announces Revamped Homepage
  • $140 to $145 Million in 2026 Projected and Profiled in New BD Deep Research Report on its Position in $57 Billion US Marine Industry; N Y S E: OTH
  • Really Cool Music Releases Its Fourth Single - "So Many Lost Years"
  • MGN Logistics Acquires Fast Service LLC, Fueling MyMGN Marketplace Expansion and Supercharging Expedited Coverage Nationwide
  • The Wait is Over: Salida Wine Festival Announces Triumphant 2026 Return After Seven-Year Hiatus
  • Graduates With $40K in Student Debt Are Buying Businesses Instead of Taking Entry-Level Jobs
  • Tatt:Magic Unveils Breakthrough Tattoo Recovery System with Faster Recovery No Itch, for Vibrant ink
  • Anne Seidman: Within the Lines
  • How Democrats Made Healthcare More Expensive in 2026
_catLbl0 _catLbl1

Popular on ncarol.com

  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 144
  • "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society - 115
  • VDG Virtuoso Emerges as a New-Model Independent Industry Figure Blending Artist, Executive, and Infrastructure Builder - 104
  • Walmart $WMT and COSTCO.COM $COST Distribution as SonicShieldX™ Platform Sets the Stage for Accelerated Growth in 2026: AXIL Brands (N Y S E: AXIL)
  • A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
  • Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
  • Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
  • Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
  • CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
  • LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio

Similar on ncarol.com

  • Preston Dermatology & Skin Surgery Center Wins Gold and Bronze in Prestigious Annual DIAMOND Awards
  • Imagen Golf Launches "Precision Lessons" with Trackman iO in Newtown, PA
  • The Stork Foundation Announces 2025 Year-End Impact and Grant Awards Amid Rising National Demand
  • Japan's Patented "Hammock'n" Smartphone Band Targets Hand Fatigue From Long Phone Use
  • CCHR: Harvard Review Exposes Institutional Corruption in Global Mental Health
  • Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)
  • American Laser Study Club Announces 2026 Kumar Patel Prize in Laser Surgery Recipients: Ann Bynum, DDS, and Boaz Man, DVM
  • Lineus Medical Completes UK Registration for SafeBreak® Vascular
  • How Democrats Made Healthcare More Expensive in 2026
  • FrostSkin Launches Kickstarter Campaign for Patent-Pending Instant-Chill Water Purification Bottle
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute